Labcorp Biopharmaceutical CMC Services: Antibody drug-conjugates (ADCs), Analytical considerations for QC release, stability testing, characterization and comparability

Melissa Usher

Melissa joined Labcorp in April of 2024 as the Quality Director of the West Division. After serving as a Medical Lab Technician in the U.S. Navy, she spent over 20 years in pharmaceutical, medical device, and biologics manufacturing. She has a wide variety of experience, having worked in laboratory, individual contributor, management, and leadership roles across Quality Control and Quality Assurance functions. She also has experience with Lean Enterprise, participating in and facilitating methodologies such as kaizen, kanban, and 5S.

The Liver Disease You Might Not (But Should) Know About: Nonalcoholic Steatohepatitis (NASH/MASH)

If you’ve never heard of NASH/MASH, you’re not alone. NASH/MASH is a chronic, silent liver disease that worsens over time.

NASH/MASH and NAFLD/MASLD: Screening and Diagnostic Testing

The screening practice for non-alcoholic fatty liver disease (NAFLD/MASLD) and non-alcoholic steatohepatitis (NASH/MASH) depends on highly variable global guidelines. Screening refers to checking for a disease in the absence of symptoms. Early detection through screening increases the likelihood of successfully treating the disease. In the US, high-risk populations for NAFLD/MASLD and NASH/MASH are screened through laboratory tests, imaging, and, sometimes, a liver biopsy to determine if they meet the criteria to be diagnosed with NAFLD/MASLD or NASH/MASH.